(RTTNews) - Seattle Genetics Inc. (SGEN) said that it will receive a milestone payment from Roche triggered by European Commission conditional marketing authorisation for Polivy.
Polivy is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics' technology. It was developed and is commercialized by Roche/Genentech.
Polivy was approved in combination with bendamustine plus MabThera for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who are not candidates for a haematopoietic stem cell transplant.
Polivy was granted PRIME designation by the European Medicines Agency for the treatment of people with R/R DLBCL in 2017.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
